Omacor is a medicine containing the active ingredient(s) omega-3-acid ethyl esters-90. On this page you will find out more about Omacor, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: omega-3-acid ethyl esters-90
Information for medicine and pack size:
Omacor 1 g soft capsule, 28
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
Post Myocardial Infarction: Adjuvant treatment in secondary prevention after myocardial infarction, in addition to other standard therapy (e.g., statins, antiplatelet medicinal products, beta- blockers, ACE inhibitors). Hypertriglyceridaemia: Endogenous hypertriglyceridaemia as a supplement to diet when dietary measures alone are insufficient to produce an adequate response. Treatment is indicated for the following types of dyslipidaemia (Fredrickson classification) only: -Type IV & V as monotherapy and with close monitoring of LDL-C levels. - Type IIb as add-on therapy to statins, when control of triglycerides with statins has been shown to be insufficient. Patients with higher baseline levels of triglycerides are more likely to exhibit a better response to Omacor. Omacor is not indicated in exogenous hypertriglyceridaemia (Type 1 hyperchylomicronaemia). There are insufficient data to support the use in patients with secondary endogenous hypertriglyceridaemia including patients with diabetes mellitus.
Table of characteristics
Transparent, oblong (size 20) soft gelatin capsule, light yellow oil fill.
Images are the copyright of the Pharmacy Guild of Australia
|Dosage Form||Capsule, soft|
|Route of administration||Oral|
100: Prescription Only Medicine, or Prescription Animal Remedy
28: Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
Pack type 1
|Storage temperature||Store below 30 degrees Celsius|
|Storage conditions||Do not Freeze,Do not Refrigerate,Protect from Light|
|Life time||30 Months|
We were unable to verify that this medicine is available on the PBS (Pharmaceutical Benefits Scheme). Please consult your pharmacist if you need further information
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.